← All Engene Holdings INC filings

Engene Holdings INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ENGN
Engene Holdings INC
10-K/A: enGene Holdings Amends 10-K for Governance Details
enGene Holdings Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K to include previously omitted Part III information regarding corporate governance and executive compensation.
NASDAQ
ENGN
Engene Holdings INC
10-K: enGene Holdings Reports FY2025 Losses, Advances Bladder Cancer Therapy
enGene Holdings Inc. reported increased net losses for fiscal year 2025 while advancing its lead bladder cancer therapy, detalimogene, towards a planned BLA submission in late 2026.
NASDAQ
ENGN
Engene Holdings INC
10-K/A: enGene Holdings Files Amendment No. 1 to Form 10-K to Include Part III Information
enGene Holdings Inc. files an amendment to its annual report on Form 10-K to include previously omitted Part III information regarding directors, executive officers, and corporate governance.
NASDAQ
ENGN
Engene Holdings INC
10-K: enGene Holdings Inc. Files 10-K Report, Highlights Clinical Progress and Financial Position
enGene Holdings Inc. released its annual 10-K filing, detailing its clinical progress with detalimogene, financial status, and strategic direction.
NASDAQ
ENGN
Engene Holdings INC
10-K: enGene Holdings Inc. Details Share Structure and Warrants in 10-K Filing
enGene Holdings Inc. provides a detailed overview of its share capital, warrants, and corporate governance structure in its latest 10-K filing.